Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Influenza01:27

Influenza

30
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
30
Vaccine Production01:23

Vaccine Production

30
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
30

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal Delivery of an RSV A2-Derived Pre-F VLP Vaccine Induces Robust Mucosal and Systemic Immunity Against RSV B Strain Without Enhanced Disease.

Immune network·2026
Same author

Influenza Virus-Like Particles Displaying <i>Leishmania donovani</i> Promastigote Surface Antigen Induce Cross-Protective Immunity.

ACS infectious diseases·2026
Same author

Dose- and time-dependent dissemination of viable Leishmania amazonensis following experimental footpad infection in mice.

Acta tropica·2026
Same author

Purinergic Signaling, HIF, and ROS Interactions in Myocardial I/R Injury: Therapeutic Potential and Future Prospective.

Cells·2026
Same author

Self-assembled influenza a neuraminidase virus-like particle vaccination confers protection against influenza B virus.

Nanomedicine (London, England)·2026
Same author

Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity.

Journal of virology·2026

Related Experiment Video

Updated: Mar 22, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Progress in developing virus-like particle influenza vaccines.

Fu-Shi Quan1, Young-Tae Lee2, Ki-Hye Kim2

  • 1a Department of Medical Zoology , Kyung Hee University School of Medicine , Seoul , Korea.

Expert Review of Vaccines
|April 9, 2016
PubMed
Summary

Virus-like particle (VLP) vaccines show promise for influenza, offering safety and efficacy. This review explores their potential for seasonal, pandemic, and avian flu, aiming for broad protection.

Keywords:
Influenza viruscross protectionstrain-specific protectionvaccinesvirus-like particles

More Related Videos

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.3K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

9.0K

Related Experiment Videos

Last Updated: Mar 22, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.3K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

9.0K

Area of Science:

  • Vaccinology
  • Virology
  • Biotechnology

Background:

  • Recombinant vaccines utilizing virus-like particles (VLPs) and nanoparticles demonstrate significant safety and efficacy in preclinical and clinical trials.
  • Advanced molecular engineering enables the expression of enveloped VLP vaccines with membrane-anchored, immunogenic proteins that mimic native viral surface protein conformations.

Purpose of the Study:

  • To review recent advancements in influenza virus-like particle (VLP) vaccines for human use.
  • To assess the immunogenicity and efficacy of influenza VLP vaccines, including homologous and cross-protective responses.
  • To discuss current limitations in influenza vaccination and explore future directions for broadly cross-protective vaccines.

Main Methods:

  • Literature review of recent developments in influenza VLP vaccine technology.
  • Analysis of studies evaluating the immunogenicity and efficacy of VLP vaccines against various influenza strains.
  • Examination of molecular engineering strategies for VLP vaccine development.

Main Results:

  • Influenza VLP vaccines have shown successful safety and efficacy profiles in human studies.
  • VLP technology allows for the presentation of viral surface proteins in a conformationally native state, enhancing immunogenicity.
  • Studies indicate potential for both homologous and cross-protective immunity against influenza viruses.

Conclusions:

  • Influenza VLP vaccines represent a promising platform for developing next-generation vaccines.
  • Further research is needed to overcome limitations of current strategies and achieve broadly cross-protective influenza vaccines.
  • The development of novel VLP-based vaccination strategies holds potential for improved global influenza control.